Dublin-based Medtronic plc will start a trial to assess two drug-eluting stents (DES) with a shorter-than-standard, one-month regimen of dual antiplatelet therapy (DAPT) in patients who are at high bleeding risk. Current drug-eluting stent guidelines call for six months of the accompanying drug therapy, which can be risky for older patients and others at risk for excessive bleeding.

One criticism of genetic approaches to cancer treatment has been that they don't actually improve care for most patients. But as the number of targeted drugs has expanded exponentially as part of the ongoing cancer immunotherapy push and genetic research has advanced, that may no longer be the case.